100 related articles for article (PubMed ID: 37305830)
21. The role of 11-oxygenated androgens in prostate cancer.
Snaterse G; Hofland J; Lapauw B
Endocr Oncol; 2023 Jan; 3(1):e220072. PubMed ID: 37434644
[TBL] [Abstract][Full Text] [Related]
22. Precision medicine for prostate cancer.
Galazi M; Rodriguez-Vida A; Ng T; Mason M; Chowdhury S
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1305-15. PubMed ID: 25354871
[TBL] [Abstract][Full Text] [Related]
23. A case report of multiple primary prostate tumors with differential drug sensitivity.
Wilkinson S; Harmon SA; Terrigino NT; Karzai F; Pinto PA; Madan RA; VanderWeele DJ; Lake R; Atway R; Bright JR; Carrabba NV; Trostel SY; Lis RT; Chun G; Gulley JL; Merino MJ; Choyke PL; Ye H; Dahut WL; Turkbey B; Sowalsky AG
Nat Commun; 2020 Feb; 11(1):837. PubMed ID: 32054861
[TBL] [Abstract][Full Text] [Related]
24. Asian trends in primary androgen depletion therapy on prostate cancer.
Akaza H
Cancer Biol Med; 2013 Dec; 10(4):187-91. PubMed ID: 24349828
[TBL] [Abstract][Full Text] [Related]
25. Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making.
Tao DL; Bailey S; Beer TM; Foss E; Beckett B; Fung A; Foster BR; Guimaraes A; Cetnar JP; Graff JN; Eilers KM; Small EJ; Corless CL; Thomas GV; Alumkal JJ
JCO Precis Oncol; 2017; 1():. PubMed ID: 31650098
[TBL] [Abstract][Full Text] [Related]
26. Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review.
Kouroukli O; Bravou V; Giannitsas K; Tzelepi V
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398199
[TBL] [Abstract][Full Text] [Related]
27. Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer.
Pan H; Jansson KH; Beshiri ML; Yin J; Fang L; Agarwal S; Nguyen H; Corey E; Zhang Y; Liu J; Fan H; Lin H; Kelly K
Oncotarget; 2017 Sep; 8(44):77181-77194. PubMed ID: 29100379
[TBL] [Abstract][Full Text] [Related]
28. Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
Maitland NJ
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477370
[TBL] [Abstract][Full Text] [Related]
29. Genomic Deletion at
Poluri RTK; Audet-Walsh É
Front Oncol; 2018; 8():246. PubMed ID: 30009155
[TBL] [Abstract][Full Text] [Related]
30. Androgen deprivation triggers a cytokine signaling switch to induce immune suppression and prostate cancer recurrence.
Sha K; Zhang R; Maolake A; Singh S; Chatta G; Eng KH; Nastiuk KL; Krolewski JJ
bioRxiv; 2024 Feb; ():. PubMed ID: 38405929
[TBL] [Abstract][Full Text] [Related]
31. Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update).
Zhu Y; Ye D;
Cancer Manag Res; 2020; 12():2127-2140. PubMed ID: 32273753
[TBL] [Abstract][Full Text] [Related]
32.
Khatami F; Shahriari S; Aminimoghaddam S; Klashami ZN; Farahani MS; Teimoori-Toolabi L; Amoli MM; Asadi M; Rashidi BH
Epigenomics; 2023 Apr; 15(8):507-516. PubMed ID: 37345350
[No Abstract] [Full Text] [Related]
33. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.
Whang YE; Wu X; Suzuki H; Reiter RE; Tran C; Vessella RL; Said JW; Isaacs WB; Sawyers CL
Proc Natl Acad Sci U S A; 1998 Apr; 95(9):5246-50. PubMed ID: 9560261
[TBL] [Abstract][Full Text] [Related]
34. A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics.
SantaLucia J
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1460-5. PubMed ID: 9465037
[TBL] [Abstract][Full Text] [Related]
35. Dependence of the melting temperature of DNA on salt concentration.
Schildkraut C
Biopolymers; 1965; 3(2):195-208. PubMed ID: 5889540
[No Abstract] [Full Text] [Related]
36.
Alzoubi A; Al Bashir S; Smairat A; Alrawashdeh A; Haddad H; Kheirallah K
J Med Life; 2023 Apr; 16(4):593-598. PubMed ID: 37305830
[TBL] [Abstract][Full Text] [Related]
37. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
38. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
Ferraldeschi R; Nava Rodrigues D; Riisnaes R; Miranda S; Figueiredo I; Rescigno P; Ravi P; Pezaro C; Omlin A; Lorente D; Zafeiriou Z; Mateo J; Altavilla A; Sideris S; Bianchini D; Grist E; Thway K; Perez Lopez R; Tunariu N; Parker C; Dearnaley D; Reid A; Attard G; de Bono J
Eur Urol; 2015 Apr; 67(4):795-802. PubMed ID: 25454616
[TBL] [Abstract][Full Text] [Related]
39. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
40. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
